Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Condition Directory

Gastric Cancer clinical trials

Directory of U.S. ClinicalTrials.gov public records for Gastric Cancer. Browse Gastric Cancer recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 30, 2026 Report an issue

ClinicalTrials.gov public records Last synced Oct 30, 2026, 5:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1090
Shown on this page
12
Current sort
Recently updated
Condition scope
Gastric Cancer
Additional filters apply within this condition.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

How Gastric Cancer studies are organized in the registry

Gastric cancer studies are often registered together with gastroesophageal junction (GEJ) tumors, and many list both. HER2 status appears in this portfolio as well, marking a biomarker-defined subset. Including “gastroesophageal” in a query surfaces records that a plain “gastric” search can miss.

Terms that often appear in related listings
gastroesophageal junction GEJ HER2 advanced gastric

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Filter and sort this condition

These controls apply only within Gastric Cancer. Default order is Recently updated. Add location, sponsor, treatment, or recruitment status to narrow this condition page further.

Reset condition filters
Clear filters
Showing 361–372 of 1,090 matching trials for Gastric Cancer.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Recruiting Not applicable Interventional

CONFIRM: Magnetic Resonance Guided Radiation Therapy

NCT04368702
View directory record Official record
Conditions
Gastric Cancer, Invasive Breast Cancer, in Situ Breast Cancer, Mantle Cell Lymphoma, Larynx Cancer, Bladder Cancer
Interventions
Viewray MRIdian® Linac
Radiation
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 30, 2026, 5:10 AM EDT
Recruiting Phase 1 Interventional

Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors

NCT03740256
View directory record Official record
Conditions
Bladder Cancer, Head and Neck Squamous Cell Carcinoma, Cancer of the Salivary Gland, Lung Cancer, Breast Cancer, Gastric Cancer, Esophageal Cancer, Colorectal Cancer, Pancreatic Adenocarcinoma, Solid Tumor
Interventions
CAdVEC
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2038
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 30, 2026, 5:10 AM EDT
Recruiting No phase listed Observational

CTNNA1 Familial Expansion Study

NCT05126290
View directory record Official record
Conditions
Cancer Gene Mutation, Gastric Cancer, Breast Cancer
Interventions
Collection of personal and family history from CAFÉ Study participants
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 30, 2026, 5:10 AM EDT
Active, not recruiting Phase 2 Interventional

Study of Sequential Systemic Therapy + Intraperitoneal Paclitaxel in Gastric/GEJ Peritoneal Carcinomatosis

NCT04762953
View directory record Official record
Conditions
Gastric Cancer, Peritoneal Carcinomatosis, Gastroesophageal Junction Adenocarcinoma
Interventions
Paclitaxel, Leucovorin, Fluorouracil
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 30, 2026, 5:10 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery

NCT03008278
View directory record Official record
Conditions
Metastatic Esophageal Carcinoma, Metastatic Gastric Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Gastroesophageal Junction Adenocarcinoma, Stage III Esophageal Cancer AJCC v7, Stage III Gastric Cancer AJCC v7, Stage IV Esophageal Cancer AJCC v7, Stage IV Gastric Cancer AJCC v7, Unresectable Esophageal Carcinoma, Unresectable Gastric Carcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma
Interventions
Olaparib, Ramucirumab
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
32
States / cities
Corona, California • Duarte, California • Lancaster, California + 24 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 30, 2026, 5:10 AM EDT
Terminated Phase 1 Interventional

A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation

NCT06560645
View directory record Official record
Conditions
Advanced Solid Tumor, Metastatic Solid Tumor, Non-small Cell Lung Carcinoma, SMARCA4 Mutation, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastric Squamous Cell Carcinoma, Gastroesophageal Junction Adenocarcinoma, Gastroesophageal Junction Squamous Cell Carcinoma
Interventions
PRT7732
Drug
Lead sponsor
Prelude Therapeutics Incorporated
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
11
States / cities
San Francisco, California • Detroit, Michigan • New York, New York + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Oct 30, 2026, 5:10 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

A Study Collecting Health Information to Understand and Prevent Gastric Cancer

NCT06370143
View directory record Official record
Conditions
Gastric Atrophy, Gastric Intestinal Metaplasia, Dysplasia, Gastric Adenocarcinoma, Gastric Cancer
Interventions
Questionnaire
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2036
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2026 · Synced Oct 30, 2026, 5:10 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas

NCT05583149
View directory record Official record
Conditions
Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma, Aggressive B-cell NHL, Diffuse Large B-cell Lymphoma (DLBCL), De Novo or Transformed Indolent B-cell Lymphoma, DLBCL, Nos Genetic Subtypes, T Cell/Histiocyte-rich Large B-cell Lymphoma, EBV-Positive DLBCL, Nos, Primary Mediastinal [Thymic] Large B-cell Lymphoma (PMBCL), High-Grade B-Cell Lymphoma, Nos, C-MYC/BCL6 Double-Hit High-Grade B-Cell Lymphoma, Grade 3b Follicular Lymphoma, C-MYC/BCL2 Double-Hit High-Grade B-Cell Lymphoma
Interventions
ACALABRUTINIB, LISOCABTAGENE MARALEUCEL, Lymphodepleting chemotherapy
Drug
Lead sponsor
Patrick C. Johnson, MD
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 30, 2026, 5:10 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors

NCT05070247
View directory record Official record
Conditions
Pancreatic Cancer, Hepatocellular Cancer, Mesothelioma, Breast Cancer, Gastric Cancer, Esophageal Cancer, Nasopharyngeal Cancer, Kidney Cancer, Squamous Cell Cancer of Head and Neck (SCCHN), Non-small Cell Lung Cancer (NSCLC), Non-squamous
Interventions
TAK-500, Pembrolizumab, Tocilizumab, Dexamethasone
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
12
States / cities
Birmingham, Alabama • Duarte, California • La Jolla, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 30, 2026, 5:10 AM EDT
Completed Phase 1 Interventional

A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers

NCT05360680
View directory record Official record
Conditions
Colorectal Cancer, Gastric Cancer, Pancreatic Cancer, Ovarian Cancer
Interventions
CUE-102
Drug
Lead sponsor
Cue Biopharma
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
15
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 30, 2026, 5:10 AM EDT
Recruiting Phase 1Phase 2 Interventional

Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies

NCT03539822
View directory record Official record
Conditions
Gastric Cancer, Esophageal Adenocarcinoma, Hepatocellular Carcinoma, Colorectal Cancer
Interventions
Cabozantinib, Durvalumab, Tremelimumab
Drug
Lead sponsor
Anwaar Saeed
Other
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
2
States / cities
Westwood, Kansas • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 30, 2026, 5:10 AM EDT
Recruiting Phase 1 Interventional

A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors

NCT07317505
View directory record Official record
Conditions
Cancer, Cancer (Solid Tumors)
Interventions
JMT108
Drug
Lead sponsor
Conjupro Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
3
States / cities
Huntersville, North Carolina • Dallas, Texas • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 30, 2026, 5:10 AM EDT

About this Gastric Cancer clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Gastric Cancer as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results
Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Gastric Cancer.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all condition pages, browse by drug or therapy, browse by U.S. city, browse by sponsor, or open the full search for Gastric Cancer.